Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tecovirimat,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : SIGA Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)
Details : TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX und...
Product Name : Tpoxx
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2022
Lead Product(s) : Tecovirimat,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : SIGA Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable